Virtu KCG Holdings’s Ligand Pharmaceuticals LGND Stock Holding History

Virtu KCG Holdings’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-9,554	Closed	-$606K	–	3481
2016 Q4	$606K	Buy	+9,554	New	+$603K	0.01%	1286
2016 Q2	–	Sell	-6,268	Closed	-$419K	–	3166
2016 Q1	$419K	Buy	+6,268	New	+$381K	0.01%	1372
2015 Q3	–	Sell	-6,550	Closed	-$412K	–	3620
2015 Q2	$412K	Buy	+6,550	New	+$357K	0.01%	1679
2015 Q1	–	Sell	-9,158	Closed	-$304K	–	3550
2014 Q4	$304K	Buy	+9,158	New	+$298K	0.01%	2323
2014 Q3	–	Sell	-7,496	Closed	-$291K	–	3851
2014 Q2	$291K	Buy	+7,496	New	+$304K	﹤0.01%	2608

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Virtu KCG Holdings's LGND Position: Q1 2017 in Review

Virtu KCG Holdings sold out of Ligand Pharmaceuticals (LGND) in Q1 2017, closing a stake of 9,554 shares — an estimated $606K sold.

Virtu KCG Holdings first reported a position in LGND in Q2 2014 and held it in 5 quarters. The position peaked at $606K in Q4 2016. 256 funds tracked by Wall St. Rank hold LGND as of Q1 2017.

Virtu KCG Holdings reported no remaining Ligand Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Virtu KCG Holdings sold 9,554 Ligand Pharmaceuticals shares in Q1 2017, an estimated $606K.
Virtu KCG Holdings first reported a position in Ligand Pharmaceuticals in Q2 2014 and held it in 5 quarters.
Virtu KCG Holdings's Ligand Pharmaceuticals position peaked at $606K in Q4 2016.
256 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2017.

Based on Virtu KCG Holdings's 13F filing for Q1 2017, filed 12 May 2017.